MPLT
NASDAQ:MPLTNASDAQ
7 announcements
Credibility Score85%
MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
OverhypedModerate hypedeteriorating
MapLight reports rising losses but maintains strong cash to fund long-term clinical trials.
19 minutes ago
▼
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
Routinedeteriorating
MapLight shares plunged 65% after failed Phase 2 trial; legal investigation now underway.
3 Aug 2026, 06:47 UTC
▼
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
Overhypedunclear
Primary endpoint missed; only a small subgroup showed benefit, so risk remains high.
22 Jun 2026, 11:21 UTC
▼
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Overhypeddeteriorating
MapLight is burning cash fast, with real results still years away and no revenue yet.
18 May 2026, 09:08 UTC
▼